Investors seeking early exposure to high-impact life sciences innovations will have a direct line to management teams at the upcoming Life Sciences Virtual Investor Forum on September 17, 2026. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the online event features seven companies spanning photothermal cancer therapy, cannabinoid-based treatments, precision drug delivery, novel antibiotics, and advanced respiratory imaging. The forum’s significance lies in its ability to democratize access to emerging biotech and pharmaceutical firms that are tackling some of medicine’s most persistent challenges, from drug-resistant infections to fibrosis and solid tumors.
The lineup includes Sona Nanotech Inc., which is developing a photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical, focused on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; Amplia Therapeutics Ltd., advancing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis; and Adaptin Bio, Inc., which is working on precision drug delivery technologies that target tissues behind the blood-brain barrier. Also presenting are Acurx Pharmaceuticals, Inc., developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens; CytoDyn Inc., studying a humanized monoclonal antibody in solid-tumor oncology; and 4DMedical Ltd., which offers FDA-cleared four-dimensional respiratory imaging. Each company will deliver a 30-minute live presentation followed by audience Q&A, with replays available on the B2i Digital and OTC Markets YouTube channels.
The forum matters because it provides a rare opportunity for investors to hear directly from executives about pipeline progress, clinical strategies, and market potential in real time. David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the interactive value of the format: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” That candid engagement can reveal nuances not captured in press releases or financial statements, helping investors assess risks and opportunities more accurately.
For the companies, the event offers broad exposure to a global investor audience. Virtual Investor Conferences regularly features public companies from major exchanges including the NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets. B2i Digital’s marketing reach—spanning over 800 news, broadcast, and trade outlets with a combined monthly audience exceeding 330 million—amplifies each presenter’s story. Investors can register for the forum at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC and find event details and company profiles at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
The implications of this forum extend beyond a single day of presentations. As biotech and pharmaceutical innovation accelerates, such events can influence investment flows into sectors that address unmet medical needs. For instance, new antibiotics targeting priority pathogens are critical in the fight against antimicrobial resistance, while cannabinoid therapeutics and gold nanorod cancer therapies represent novel approaches that could reshape treatment paradigms. By connecting investors with these pioneers, the forum may help fuel the capital necessary to advance clinical trials and bring new therapies to market. In an era where healthcare challenges are increasingly complex, platforms that foster direct dialogue between management and investors play a vital role in driving informed investment and, ultimately, medical progress.
